Document is current
Any future updates will be listed below
-
Authors
Schaefer, Robin https://orcid.org/0000-0003-4733-4692
Donaldson, L.
Chigome, A.
Escudeiro dos Santos, M.
Lamprianou, S.
Ndembi, N.
Nwokike, J. I.
Nyambayo, P.
Palmi, V.
Renaud, F.
Gonzalez Tome, M.
Miller, V.
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-045445)
- License Information
-
More Information
Article History
Accepted: 28 October 2024
First Online: 26 January 2025
Declarations
:
: This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation (INV-045445). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.
: The Forum for Collaborative Research receives unrestricted grants from the pharmaceutical industry, including from companies involved in the development of antiretroviral drugs (ViiV Healthcare, Merck, and Gilead Sciences). These grants are provided to the organization and are not specifically linked to the present work (which is funded through a grant by the Bill & Melinda Gates Foundation). Although the Forum considers the pharmaceutical industry to be an important stakeholder, industry partners participating in Forum activities must be scientific or regulatory experts. The Forum’s meetings are not venues for marketing and investment experts.The authors (as individuals) have no relevant financial or non-financial interests to disclose.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the discussions underlying this manuscript. RS wrote the first draft of the manuscript. All authors reviewed and contributed to previous versions of the manuscript. All authors read and approved the final manuscript.
